&nbsp;

Dec 2025

Drug

pazopanib

Other Name(s): Votrient®

Quick Link(s):

Dec 2025

Regimen

CHP+POLA+RITU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade,

Lymphoma - Non-Hodgkin's Intermediate Grade

Intent: Curative

Funding:

ODB - General Benefit

prednisone

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Aggressive Histology Lymphoma

Drugs Used:

prednisone,

riTUXimab (Unfunded),

polatuzumab vedotin (Unfunded),

DOXOrubicin,

cyclophosphamide

Quick Link(s):

Regimen Monograph

Jan 2026

Drug

pamidronate

Quick Link(s):

Jan 2026

Drug

polatuzumab vedotin

Other Name(s): Polivy™

Quick Link(s):

Jan 2026

Regimen

PMDR

Cancer Type:

Breast

Intent: Palliative

Drugs Used:

pamidronate

Quick Link(s):

Regimen Monograph

Jan 2026

Regimen

PMDR

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Drugs Used:

pamidronate

Quick Link(s):

Regimen Monograph

Jan 2026

Regimen

PMDR(HYPER CA)

Cancer Type:

Breast,

Central Nervous System,

Endocrine,

Gastrointestinal,

Genitourinary,

Gynecologic,

Head and Neck,

Hematologic,

Lung,

Sarcoma,

Skin,

Unknown Primary

Intent: Supportive Care, Palliative

Drugs Used:

pamidronate

Quick Link(s):

Regimen Monograph

Jan 2026

Regimen

CHP+BREN

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Intermediate Grade,

Lymphoma - T-cell

Intent: Curative, Palliative

Funding:

ODB - General Benefit

prednisone

New Drug Funding Program

Brentuximab Vedotin - In Combination with Chemotherapy for Previously Untreated Peripheral T-cell Lymphoma (PTCL)

Drugs Used:

Quick Link(s):

Regimen Monograph

Jan 2026

Regimen

CEP+BREN

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Intermediate Grade,

Lymphoma - T-cell

Intent: Curative, Palliative

Funding:

ODB - General Benefit

prednisone

New Drug Funding Program

Brentuximab Vedotin - In Combination with Chemotherapy for Previously Untreated Peripheral T-cell Lymphoma (PTCL)

ODB - General Benefit

etoposide - oral capsules

Drugs Used: